Company Intervacc AB (publ) Nasdaq Stockholm
Equities
SE0009607252
Biotechnology & Medical Research
Business Summary
Sales per Business
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Veterinary Vaccines
100.0
%
| 5 | 100.0 % | 10 | 100.0 % | +84.77% |
Sales per region
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 5 | 100.0 % | 10 | 100.0 % | +84.77% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jonas Sohlman
CEO | Chief Executive Officer | - | 23-08-20 |
Jan Persson
DFI | Director of Finance/CFO | - | 20-02-05 |
Andrew Waller
CTO | Chief Tech/Sci/R&D Officer | - | 20-06-10 |
Patrik Hellberg
CIO | Chief Investment Officer | - | - |
Tim Wood
LAW | General Counsel | - | 18-07-31 |
Corporate Officer/Principal | 45 | 10-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Boel Sundvall
BRD | Director/Board Member | 65 | 22-12-31 |
Chairman | 56 | - | |
Edwin Torr
BRD | Director/Board Member | 63 | - |
Director/Board Member | 63 | 08-12-31 | |
Bengt Guss
FOU | Founder | 66 | 00-12-31 |
Niels Holcke
BRD | Director/Board Member | - | 19-12-31 |
Michela de Carli
BRD | Director/Board Member | - | 21-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 75,736,264 | 59,198,500 ( 78.16 %) | 0 | 78.16 % |
Company contact information
Intervacc AB
Västertorpsvägen 135 Hägersten
129 44, Stockholm
+46 8 12 01 06 00
http://www.intervacc.comSector
1st Jan change | Capi. | |
---|---|---|
+11.91% | 118B | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.82% | 21.96B | |
-10.12% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B |